Research for New Drugs against Tuberculosis and Other Mycobacterial Diseases

Topic Information

Dear Colleagues,

Mycobacterium tuberculosis is the major etiological agent for tuberculosis (TB), an infectious disease. TB is the leading cause of single pathogen infection-related deaths with more than 4000 TB-related deaths reported every day worldwide. In 2019, approximately 10 million individuals were diagnosed with TB and an estimated 25% of the population suffered from latent TB. The World Health Organization (WHO) has aimed to reduce TB-related deaths and infections by 90% and 80% by 2030, respectively, when compared with those reported in 2015. To achieve this goal, novel safe, and effective antibiotics must be developed against intracellular, non-replicant, and resistant strains. On the other hand Non-tuberculous mycobacteria (NTM) are ubiquitously present in the environment, but NTM diseases occur infrequently. NTM are generally considered to be less virulent than Mycobacterium tuberculosis, however, these organisms can cause diseases in both immunocompromised and immunocompetent hosts. Therefore, there is an urgent need to develop novel drugs for effectively treating MDR-TB, and NTM decreasing the treatment duration, and minimizing the toxicity and cost of the drugs. This Research Topic requires the coordinated effort of multiple scientific disciplines as microbiology, pharmacology, chemistry, medical and correlated. We welcome your contributions on all aspects of novel drugs for treating MDR-TB in this Topic.

Prof. Dr. Fernando Rogério Pavan
Prof. Dr. Alzir Azevedo Batista
Dr. Adelino Vieira de Godoy Netto
Dr. Daniela Fernandes Ramos
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomedicines biomedicines	4.757	3.0	2013	17.4 Days	2200 CHF	Submit
Future Pharmacology futurepharmacol	-	-	2021	19.7 Days	1000 CHF	Submit
Journal of Clinical Medicine jcm	4.964	4.4	2012	18 Days	2600 CHF	Submit
Pharmaceutics pharmaceutics	6.525	6.0	2009	15.9 Days	2600 CHF	Submit
Tropical Medicine and Infectious Disease tropicalmed	3.711	4.8	2016	15.1 Days	2000 CHF	Submit

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomedicines Future Pharmacology JCM Pharmaceutics TropicalMed

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

get_app

subject

View online as:
Abstract Page
Full-Text HTML

Open AccessArticle

Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria

by

Débora Leite Campos

,

Fernanda Manaia Demarqui

,

Mariana Cristina Solcia

,

Paula Carolina de Souza

,

Pedro Ivo da Silva Maia

,

Victor Marcelo Deflon

and

Fernando Rogério Pavan

Biomedicines 2022, 10(10), 2398; https://doi.org/10.3390/biomedicines10102398 - 26 Sep 2022

Cited by 1 | Viewed by 755

Abstract

As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite [...] Read more.

As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence. Full article

(This article belongs to the Topic Research for New Drugs against Tuberculosis and Other Mycobacterial Diseases)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1